US EditionCRT 2025: AGENT IDE trial results “consistent” out to two years using DCB in ISR - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
CRT 2025: AGENT IDE trial results “consistent” out to two years using DCB in ISR - Cardiovascular News
Jeffrey Moses Consistent results have been seen out to two years in the AGENT investigational device exemption (IDE) trial, the first US randomised trial investigating the safety and efficacy of the use of a drug-coated balloon (DCB) for the treatment of coronary in-stent restenosis (ISR). Jeffrey Moses (Columbia University Medical Center, New York and St Francis Heart Center, Roslyn, USA) presented the trial’s two-year findings at the 2025 Car…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
